SUMMARY Changes in left ventricular systolic and diastolic function and outflow gradient were evaluated in patients with obstructive hypertrophic cardiomyopathy after intravenous acute treatment with verapamil (15 patients) and after six months of oral chronic treatment (11 patients 
524 15 -74 (mean 52) years) with clinical, echocardiographic, haemodynamic, and angiographic findings typical of hypertrophic obstructive cardiomyopathy were studied. No patient had coronary artery disease, pnmary valve disease, or hypertension. All had been treated previously for variable periods with the beta blocker propranolol at a mean dose of 370 mg/day. Thirteen of 15. patients continued to have chest pain, dyspnoea, or presyncope and were therefore considered for treatment with verapamil. The remaining two patients had intolerable side effects with propranolol. The study was approved by the Committee on Human Research, and each patient gave written informed consent. No complications occurred during any of the studies. STUDY 
DESIGN
On entry to the study each patient was interviewed to assess the severity of symptoms. Chest pain and dyspnoea were graded according to the New York Heart Association classification, and the presence or absence of syncope or presyncope were noted. The standard 12 lead electrocardiograms were reviewed and the degree of left ventricular hypertrophy assessed according to the Sokolow index.9 Treatment with propranolol was discontinued at least 48 hours before cardiac catheterisation. All 15 patients underwent initial cardiac catheterisation by the femoral approach. Right heart catheterisation was performed with a triple lumen balloon flotation catheter to determine right atrial, pulmonary arterial, and pulmonary capillary wedge pressures, and cardiac output was determined in Although in some patients the voltage of the QRS complex in the precordial electrocardiographic leads decreased, in the group as a whole there was no appreciable change in the Sokolow index after chronic oral treatment.
HAEMODYNAMIC EFFECTS
Acute intravenous verapamil caused a statistically significant decrease in mean (-+SD) arterial pressure from 92±12 to 82+13 mm Hg (Table 1) . Systemic vascular resistance tended to decrease and cardiac index to increase, although these changes were not statistically significant. Heart rate and end diastolic pressure did not change significantly. In all 15 patients a left ventricular outflow pressure gradient was present at rest before verapamil treatment. In six patients the resting gradient decreased after intravenous verapamil, whereas in the remaining nine there was either an increase or no change in the resting gradient. In the group as a whole there was no significant change in the mean resting or provocable gradient after intravenous verapamil.
In 11 of 12 patients the haemodynamic effects of chronic oral treatment with verapamil could be assessed. Though heart rate tended to be slower during chronic treatment, the mean changes were not statistically significant. There was no significant change in mean arterial pressure, systemic vascular resistance, cardiac index, or left ventricular end diastolic pressure after chronic treatment. Similarly, there was no change in pulmonary capillary wedge pressure, mean pulmonary artery pressure, right atrial pressure, or pulmonary vascular resistance. Changes in resting and provocable left ventricular outflow gradients after chronic treatment could be assessed in 11 patients, and there was a variable response. In five patients the resting gradient decreased, and in the remaining six there was no change. In the group as a. whole neither the mean resting nor the provocable gradient changed significantly after chronic treatment. There was also no correlation between changes in left ventricular outflow gradient and improvement in symptoms.
CHANGES IN SYSTOLIC FUNCTION
Changes in ejection fraction, mean normalised systemic ejection rate, end systolic pressure to end systolic volume ratio, and stroke volume index were determined in 13 patients after intravenous verapamil and in 11 patients after six months of oral treatment ( After chronic treatment there was an increase in end diastolic volume in seven of the 10 patients in whom these data were available. In the remaining three, there was no change. In the group as a whole there was a significant increase in end diastolic volume index from 86± 18 to 110± 13 (p<0-02). Changes in end diastolic pressure were variable, but the mean left ventricular end diastolic pressure did not change (Fig.  2) . In four patients the diastolic pressure-volume curve shifted to the right or downwards and to the right; in one patient no obvious change occurred, and in two there was a shift upwards and to the left (Fig.  3 ).
Discussion
The results of the present study confirm that many patients with hypertrophic cardiomyopathy derive relief of symptoms from chronic treatment with verapamil. The patients in this study had symptoms despite taking relatively large doses of propranolol, and in most patients dyspnoea, chekt pain, and presyncope improved after oral treatment with verapamil. We did not find any adverse reactions in our patients, although these have been reported by
The role of outflow obstruction in the origin of symptoms remains controversial."I Dyspnoea, chest pain, and presyncope frequently occur with exertion. All the patients in this study had haemodynamic features of left ventricular outflow obstruction before 526 oL_ group.bmj.com on June 15, 2017 -Published by http://heart.bmj.com/ Downloaded from Verapamil in hypertrophic cardiomyopathy treatment with verapamil. Though the resting outflow pressure gradient tended to be lower after chronic treatment, the provocable gradient remained unchanged. The fact that in individual patients improvement in symptoms did not correlate with the change in provocable gradient (akin to the exercise induced gradient) after treatment suggests that factors other than obstruction to outflow are responsible for them. This impression is substantiated by the finding that subgroups of patients with hypertrophic cardiomyopathy both with and without outflow obstruction have similar symptoms. "
The characteristic hypercontractility and cavity obliteration in these patients has also been implicated in causing symptoms. In this study there was no deterioration in left ventricular pump function after either acute or chronic treatment. There was no significant decrease in left ventricular ejection fraction or mean normalised systolic ejection rate. Indeed, after chronic treatment, left ventricular stroke volume increased without any significant change in left ventricular end diastolic pressure, indicating improved left ventricular pump function. Improvement in left ventricular pump function has been reported also during exercise after chronic treatment with verapamil. 12 Recently, it has been suggested that the changes in the ratio of the end systolic pressure to end systolic volume reflect the changes in ventricular contractility.'3 In our patients left ventricular pressure was determined with a micromanometer catheter, and left ventricular volumes were calculated by biplane cineangiography. Thus these methods should allow reliable determination of the end systolic pressure to volume ratio. Although the ratio of end systolic pressure to volume declined after intravenous verapamil-indicating a depression of contractile function-this index of contractility remained unchanged after chronic treatment.
Left ventricular contractile function and afterload are the major determinants of the mean normalised systolic ejection rate. In our patients changes in left ventricular wall stress (afterload) were not calculated. After chronic treatment, however, end diastolic volume increased without any significant change in intraventricular pressure, indicating that, if anything, there was an increase in wall stress. Such an increase in afterload should decrease mean normalised systemic ejection rate. If contractile function were also depressed a further decrease in normalised ejection rate would be expected. Thus a lack of any change in the mean normalised ejection rate strongly suggests that there was no decrease in contractile function after chronic treatment. Radioisotope angiographic studies have also shown unaltered left ventricular ejection fraction or ejection rate. '4 In seven of 10 patients in this study left ventricular 527 end diastolic volume increased significantly after chronic treatment. One of the remaining three patients had severe mitral regurgitation before treatment, and mitral regurgitation decreased appreciably after chronic treatment. A reduction in mitral regurgitation might explain the lack of increase in end diastolic volume in this patient. In the study by Kaltenbach et al left ventricular end diastolic volume increased in six of 10 patients after chronic treatment. 5 Hanrath et al found an increase in left ventricular dimension by echocardiography in most of their patients treated long term. 15 Thus chronic treatment with verapamil appears to cause ventricular dilatation and a larger end diastolic volume in patients with hypertrophic cardiomyopathy.
The mechanisms for the increase in end diastolic volume are not entirely clear. Fluid retention and increased intravascular volume may be associated with increased intracardiac volumes. None of our patients, however, gained weight or developed peripheral oedema. Systemic venous pressure also remained unchanged. Although heart rate tended to be slower after chronic treatment, the degree of change in rate was not great enough to explain the significant increase in end diastolic volume. Decreased contractile function or increased resistance to left ventricular ejection cannot explain the increase in end diastolic volume in our patients, as the indices of contractile function and systemic vascular resistance were unchanged after chronic treatment.
Increased left ventricular diastolic compliance is another potential mechanism which can cause an increase in left ventricular end diastolic volume with a concomitant increase in stroke volume. The end diastolic pressure in our patients did not increase significantly after chronic treatment. Increased end diastolic volume with an increase in end diastolic pressure strongly suggests increased left ventricular diastolic compliance. We attempted to evaluate changes in left ventricular compliance from the shifts in the diastolic pressure-volume curve. After chronic treatment there was a shift to the right or to the right and downwards in the diastolic pressure-volume curve in four to seven patients, indicating increased diastolic compliance.
The limitations of contrast angiographic techniques in determining left ventricular volume in patients with hypertrophic cardiomyopathy must be considered. When frame by frame analysis of the contrast ventriculogram is performed it is often difficult to detect slight changes in the left ventricular silhouette from one frame to another. Accurate detection of such changes, however, is necessary for changes in diastolic compliance to be determined precisely from the shift in left ventricular pressure-volume curves. Nevertheless, this study suggests that diastolic compliance 528 can improve in some patients after chronic treatment. Lorell et al also noted a shift downwards and to the right in the diastolic pressure dimension curves after treattnent with nifedipine-another slow channel entry blocking agent-in some patients with hypertrophic cardiomyopathy. '6 The mechanism for the improved diastolic compliance in some patients receiving chronic treatment with verapamil remains unclear. We did not determine changes in intrapericardial pressures or right ventricular volumes. Thus the influence of verapamil on ventricular interaction resulting from the pericardial restraining effect contributing to the changes in left ventricular diastolic pressure-volume relations remains unknown. Improved left ventricular relaxation may be a potential mechanism for the improved diastolic compliance. In a number of studies several indices of left ventricular relaxation were determined, and an improvement in the relaxation properties was reported after treatment with verapamil in patients with hypertrophic cardiomyopathy.7 [14] [15] [16] Though in the present study changes in left ventricular relaxation were not assessed, it is possible that improved relaxation contributed to the improved diastolic compliance in some of our patients.
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